Putting an Emphasis on Patient Collaboration in MPN Treatment

Dr. Richard “Rick" Winneker discussed advice that he would provide to patients faced with a myeloproliferative neoplasm (MPN) diagnosis, putting an emphasis in personalized care and active participation in the broader MPN community. He also goes on to emphasize the importance of consulting an MPN specialist to ensure optimal care.

Winneker, who currently works with the MPN Research Foundation, creating and managing programs, was recognized at the CURE® MPN Heroes event for his dedication in uniting the patient, physician and pharmaceutical communities together in creating awareness for MPN research.

In an interview, Winneker sat down with CURE and shared his expert insights on patient care, as well as expanded on the importance of participation in groups like the MPN Research Foundation to ensure a high prioritization of research and collaboration across the field. Read more from the interview below.

Transcript:

The first thing I do when I meet a patient, rather than giving them advice right away, is ask them how they're doing. I want to understand what they're experiencing because I know it can be so different from one patient to the next. [However], my advice usually is: if possible, try to see an MPN specialist, if not directly, but perhaps a second opinion or a consultation of some kind. They're the ones that are really closely following this rapidly emerging field, [therefore] you want to make sure that you're experiencing the best possible outcomes that you can.

Secondly, I would say be your own best advocate. Not only that, [but] join the MPN Research Foundation. Work with us and be part of that solution that we're trying to bring forward. We want to hear from patients about what they care about most, in terms of what we should be doing next. See the right people and join us. I think that would be my message.

Transcript was edited for clarity and conciseness.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.